RYR1 and myopathy: However, the finding that cerivastatin is the strongest activator of RyR, at all cytosolic [Ca2+], including sub‐activating levels, supports the hypothesis that inappropriate activation of RyR1 may be the first step leading to statin‐induced myopathy.